TG Therapeutics Statistics

Total Valuation

TG Therapeutics has a market cap or net worth of EUR 3.47 billion. The enterprise value is 3.47 billion.

Market Cap	3.47B
Enterprise Value	3.47B

Important Dates

The last earnings date was Monday, August 4, 2025.

Earnings Date	Aug 4, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	145.90M
Shares Outstanding	n/a
Shares Change (YoY)	+11.99%
Shares Change (QoQ)	-0.13%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	135.14M

Valuation Ratios

The trailing PE ratio is 67.42 and the forward PE ratio is 17.49.

PE Ratio	67.42
Forward PE	17.49
PS Ratio	8.98
PB Ratio	14.75
P/TBV Ratio	14.75
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 46.23, with an EV/FCF ratio of -68.86.

EV / Earnings	67.46
EV / Sales	8.96
EV / EBITDA	46.23
EV / EBIT	47.39
EV / FCF	-68.86

Financial Position

The company has a current ratio of 3.86, with a Debt / Equity ratio of 0.92.

Current Ratio	3.86
Quick Ratio	2.81
Debt / Equity	0.92
Debt / EBITDA	2.89
Debt / FCF	-4.30
Interest Coverage	2.75

Financial Efficiency

Return on equity (ROE) is 26.63% and return on invested capital (ROIC) is 13.06%.

Return on Equity (ROE)	26.63%
Return on Assets (ROA)	9.72%
Return on Invested Capital (ROIC)	13.06%
Return on Capital Employed (ROCE)	16.18%
Revenue Per Employee	1.04M
Profits Per Employee	139,135
Employee Count	338
Asset Turnover	0.82
Inventory Turnover	0.50

Taxes

In the past 12 months, TG Therapeutics has paid 4.81 million in taxes.

Income Tax	4.81M
Effective Tax Rate	8.55%

Stock Price Statistics

Beta (5Y)	n/a
52-Week Price Change	n/a
50-Day Moving Average	n/a
200-Day Moving Average	n/a
Relative Strength Index (RSI)	n/a
Average Volume (20 Days)	8

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	11.71

Income Statement

In the last 12 months, TG Therapeutics had revenue of EUR 386.64 million and earned 51.48 million in profits. Earnings per share was 0.31.

Revenue	386.64M
Gross Profit	336.21M
Operating Income	73.10M
Pretax Income	56.29M
Net Income	51.48M
EBITDA	73.13M
EBIT	73.10M
Earnings Per Share (EPS)	0.31

Full Income Statement

Balance Sheet

The company has 214.47 million in cash and 216.73 million in debt, giving a net cash position of -2.26 million.

Cash & Cash Equivalents	214.47M
Total Debt	216.73M
Net Cash	-2.26M
Net Cash Per Share	n/a
Equity (Book Value)	235.38M
Book Value Per Share	1.62
Working Capital	419.00M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -50.34 million and capital expenditures -95,368, giving a free cash flow of -50.44 million.

Operating Cash Flow	-50.34M
Capital Expenditures	-95,368
Free Cash Flow	-50.44M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 86.96%, with operating and profit margins of 18.91% and 13.31%.

Gross Margin	86.96%
Operating Margin	18.91%
Pretax Margin	14.56%
Profit Margin	13.31%
EBITDA Margin	18.92%
EBIT Margin	18.91%
FCF Margin	n/a

Dividends & Yields

TG Therapeutics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-11.99%
Shareholder Yield	n/a
Earnings Yield	1.48%
FCF Yield	-1.45%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

TG Therapeutics has an Altman Z-Score of 5.1 and a Piotroski F-Score of 3.

Altman Z-Score	5.1
Piotroski F-Score	3